InvestorsHub Logo
Followers 41
Posts 5377
Boards Moderated 0
Alias Born 11/15/2013

Re: nidan7500 post# 436806

Wednesday, 10/25/2023 12:22:35 PM

Wednesday, October 25, 2023 12:22:35 PM

Post# of 459967
Agree and when you've seen the full data as Missling et al and it not be strong you wouldn't use this promising statement - "We also look forward to presenting in an upcoming major publication the complete dataset of the Phase 2b/3 Alzheimer’s disease trial of ANAVEX®2-73 (blarcamesine), a potential next-generation precision medicine convenient once daily oral Alzheimer’s disease treatment,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. "

Freedom is not free.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News